Pharma & Biotech Global Week in Review 30 June 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

Highlights this week included:

UK: EWCA hands down judgment on appeal in Medeva’s SPC application: Medeva BV v Comptroller General of Patents (SPC blog) (SPC blog) (IPKat)

US: Supreme Court Certiorari: Summary dispositions of Classen and Prometheus (Patent Baristas) (Patently-O)

General

Mexican Congress amends IP law – original reform project promoted by National Association of Drug Manufacturers (ANAFAM) (Patent Docs)

India: Roche-Natco update – Natco commences arguments (Spicy IP)

Netherlands: Monsanto v. Cefetra and others – parties settle (EPLAW)

UK: EWCA hands down judgment on appeal in Medeva’s SPC application: Medeva BV v Comptroller General of Patents (SPC blog) (SPC blog) (IPKat)

UK: Parallels, paranova, packaging and paramnesia: Paranova Danmark A/S, Paranova Pack A/S v Merck Sharp &Dohme Corp. (formerly Merck & Co. Inc.), Merck Sharp & Dohme B.V. and Merck Sharp & Dohme (IPKat)

US: Bio commends Supreme Court for expansive view of patentability in Bilski decision (Patently BIOtech)

US: Bilski: Supreme Court refuses to prohibit software, business method, and medical diagnostic method patents (Patent Baristas)

US: Supreme Court Certiorari: Summary dispositions of Classen and Prometheus (Patent Baristas) (Patently-O)

US: District Court New Jersey: Difficulty calculating damages and harm to brand goodwill create irreparable harm warranting preliminary injunction: Albany Molecular Research, Inc. v. Dr. Reddy’s Laboratories, Ltd. et al. (Docket Report)

US: District Court Delaware: Failure to disclose sample size of test does not constitute inequitable conduct: Senju Pharmaceutical Co. Ltd. et al v. Apotex Inc. et al. (Docket Report)

US: Update on reverse settlement agreements – Amici curiae brief filed with US Court of Appeals: In re Ciprofloxacin Hydrochloride Antitrust Litigation (IP Whiteboard) (PatLit)

US: An uneven debate on ‘takings’ in pharmaceutical patent law (Patent Docs)

Products

Aldara (Imiquimod) – US: Graceway’s injunction and Nycomed’s dismissal denied in Aldara suit (Patent Docs)

Argatroban – US: Patent for Argatroban found valid, injunction issued against Barr (Patent Docs)

Crestor (Rosuvastatin) – US: Patent infringement complaint filed following a Paragraph IV certification: AstraZeneca Pharmaceuticals LP et al. v. Glenmark Generics Inc. USA (Patent Docs)

Lexapro (Escitalopram) – US: Infosint’s infringement verdict over Lexapro overturned, patent ruled invalid (Patent Docs)

Niaspan (Niacin) – US: Patent infringement complaint filed following a Paragraph IV certification: Abbott Laboratories et al. v. Sandoz Inc.(Patent Docs)

Sutent (Sunitinib) – US: Patent infringement complaint filed following a Paragraph IV certification: Pfizer Inc. et al. v. Mylan Inc. et al.(Patent Docs)

Zetia (Ezetimibe) – US: Patent infringement complaint filed following a Paragraph IV certification: Schering Corporation et al. v. Mylan Pharmaceuticals Inc. et al.(Patent Docs)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: